RehApp Ltd

Life Sciences
Aim of funding: 
HMRC Advance Assurance received: 

RehApp Ltd


Founded in 2017 by consultant cardiologists, Dr Jonas EichhÖfer and Dr Ahmed Farag, the Company seeks to develop a novel app-based cardiac rehabilitation platform, called ‘RehApp’, specifically designed to support both cardiac doctors, rehabilitation nurses, and patients recovering from a recent cardiac event. According to the Company, in the UK alone, an estimated 70,000 patients have a myocardial infarction (i.e. heart attack) each year: with those surviving, around 40,000 require a level of personal and tailored rehabilitation.The platform will be designed to meet an unmet medical need in the field of cardiac rehabilitation by making use of the current available technologies, such as intuitive software, tablets, computers, smart phones and cloud-based storage. The Company’s aim is to both compliment, modernise and improve the cardiac rehabilitation service provision. Please see Item 1.Patients that would benefit directly from the use of the new platform have recently suffered from one of the following conditions:

·         Heart Attack

·         Heart surgery

·         Angina or heart failure

·         Coronary angioplasty (procedure to widen blocked or narrowed arteries)

·         Undergone an ICD implantation (Implantable cardioverter defibrillator)

Patient data inputted at the bedside by rehabilitation nurses allows RehApp to build a significant ongoing data set that has inherent value to a number of stakeholders including doctors, rehabilitation nurses, surgeons and those performing clinical research activities. The patient data inputted is synchronised with a secure cloud based hub which allows for data analyses, information management, scheduling and communication.  The Rehabilitation nurse will be able to build a personal profile for the patient which will be accessible via a smart phone, tablet or laptop.


According to industry leaders operating with global health organisations, the continued annual rise in cardiovascular disease is without doubt attributable to an unhealthy diet, being overweight, lack of exercise, and smoking. Many of these issues are lifestyle related and are correctable but require dedicated resources, intervention and ongoing commitment from the various health bodies and authorities.According to the British Heart Foundation’s Cardiovascular Disease Statistics 2014 report, more than £4.2bn was spent on treating CVD within the NHS in England in the fiscal year 2013/14. Furthermore, according to the Center for Disease Control 2015 report ‘Americans suffer 1.5 million heart attacks and strokes each year—a burden that contributes to most of the more than $320 billion in annual healthcare costs and lost productivity caused by cardiovascular disease’.  

The Deloitte September 2015 report on ‘digital health in the UK’ states that the market for mobile health apps was worth £2.2bn in 2014 with a compounded annual growth rate of around 50% suggesting that there is a continued interest for both health and fitness apps sector has significant growth potential.  

There remains a huge disparity across the globe in the rehabilitation of individuals following a cardiac event. The variable factors often include the location of the individual, available infrastructure, cost to provide the rehabilitation nurses, clinic space, rehabilitation equipment, and support administration.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.